Introduction
This article reviews the 2005-2006 research literature in the field of marine antitumour pharmacology using a format similar to the one used in our previous five reports, which covered 1998-2004. [1] [2] [3] [4] [5] The pharmacology of marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis and antiviral activities, and those affecting the cardiovascular and nervous systems, and other miscellaneous mechanisms of action has been reviewed elsewhere. [6] [7] [8] [9] [10] Consistent with our previous five reviews, only those articles reporting on antitumour pharmacology or cytotoxicity of marine compounds with well-defined chemical structures (Figs. 1 and 2) were included in the present review, and are presented in alphabetical order in Tables 1 or 2 and/or clinical pharmacology of marine chemicals with previously determined mechanisms of action has been summarised in Table 1 , and is further discussed in the text of this review. On the other hand, reports on novel marine chemicals, which demonstrated significant cytotoxicity but with as yet undetermined mechanisms of action, are shown in Table 2 . With few exceptions, studies on the preclinical antitumour pharmacology of synthetic analogues of marine metabolites as well as reports on research with marine extracts or as yet structurally uncharacterised marine chemicals are not included in this review.
2.
2005-2006. Antitumour pharmacology of marine natural products with established mechanisms of action Table 1 tures are shown in Fig. 1 ). Reports on clinical trials with some of these marine compounds are excluded from One study was published on the preclinical pharmacology of agosterol A, a polyhydroxylated sterol acetate isolated from the marine sponge Spongia sp. Ren Research on the cyclic depsipeptide aplidine, a secondgeneration didemnin analogue also known as aplidin or dehydrodidemnin B, and isolated from the Mediterranean marine tunicate Aplidium albicans continued at an active pace. Seven preclinical studies, which characterised the cellular and molecular pharmacology of aplidine, and two clinical articles were published during [2005] [2006] . Taddei and colleague 12 demonstrated that aplidine's cytotoxic activity in NIH3T3 cells involved the production of mitochondrial reactive oxygen species that induced oxidation and inactivation of low molecular weight protein-tyrosine phosphatase activity, an enzyme that appears to play a role in both tumour onset and development. Bravo and colleagues 13 that the mechanism of aplidine-induced apoptosis involved a novel and potent cell-killing mechanism that required Fas activation and clustering of additional death receptors, membrane-bound FasL and downstream signalling molecules into 'aggregated lipid rafts' through a cytoskeleton-mediated process. The observation that aplidine was rapidly incorporated into lipid rafts highlighted the significance of these lipid aggregates in the regulation of apoptosis and cancer chemotherapy. Tognon and colleagues 16 found that aplidineinduced resistance in a human ovarian cancer cell line over a period of several months, was related to the expression of the multidrug transporter Pgp, 'potentially useful pharmacological information' that may have clinical relevance. Gonzalez-Santiago and colleagues 17 examined the molecular mechanism of apoptosis induction by aplidine in human breast cancer cells. They demonstrated that aplidine disrupted glutathione homeostasis by increasing the ratio of oxidised to reduced forms, thus leading to increases in reactive oxygen species and oxidative stress. Furthermore, aplidine caused rapid activation of Rac1 small GTPase resulting in Jun N-terminal kinase (JNK) phosphorylation, which was considered critical for aplidine-induced apoptosis. There was a concomitant decrease of MKP-1 phosphatase, an enzyme overexpressed in human breast cancer and considered a 'viable target for therapeutic intervention' by enabling the expression of pro-apoptotic activity of JNK. Straight and colleagues 18 tested the hypothesis that aplidine would reduce the growth of anaplastic thyroid xenografts in mice. Interest- ingly, aplidine reduced tumour growth as well as the expression of 16 of 20 angiogenic genes investigated, suggesting that aplidine might be an effective adjunctive therapy for anaplastic thyroid cancer, an aggressive and highly lethal cancer. 
advanced malignancies. Although muscle toxicity was noted as dose limiting at doses P5 mg/m 2 , aplidine induced minor responses and tumour stabilisations in eight patients, and clinical benefit in six patients with endocrine tumours. Maroun and colleagues 20 conducted a Phase I study in 37 patients with refractory solid tumours in which a 1-h infusion of aplidine was given for 5 d every 3 weeks. Even though the regimen was well tolerated, only nine patients with progressive disease at study entry had stable disease, whilst two patients with non-small cell lung cancer and one with colorectal cancer evidenced minor responses. A preclinical study by Guittat and colleagues 21 reported that ascididemin, a pyridoacridine alkaloid isolated from the marine sponge Amphimedon sp., inhibited telomerase prostate cancer. The novel conjugate eliminated PSMAexpressing cells with picomolar efficiency in vitro as well showed therapeutic efficacy in a mouse xenograft model of androgen-independent human prostate cancer. These findings suggested that this approach merits further development as a molecularly targeted therapy of hormone-refractory prostate cancer, the second leading cause of death in men in the United States. Smith Two preclinical studies were described for the cyclopentenone prostanoid bromovulone III, which was isolated from the soft coral Clavularia viridis. 42 reported extensive preclinical evaluation of the synthetic and formulation-stable glycinate esters of cryptophycins 309 and 249, as well as other analogues in mouse and human tumours. Based on the expectation that these second-generation analogues will produce 100-1000-fold greater activity than the first clinical candidates (e.g. cryptophycin 52), and their formulation stability advantage compared to cryptophycin C-52, the authors noted that both 'C-309 and C-249 are being considered as second-generation clinical candidates'. D'Agostino and colleagues 43 described a multicentre Phase II study of a synthetic cryptophycin analogue LY355703 in 26 patients with platinum-resistant ovarian cancer, a leading cause of death from gynaecological tumours Interestingly, they found that the pancreas had the greatest concentration of radiolabel at both the high and the low doses 7 d after administration, which suggested possible efficacy in animal models for the treatment of pancreatic cancer. Park and colleagues 46 examined the pharmacology of dideoxypetrosynol A, a polyacetylene from the marine sponge Petrosia sp., by investigating the molecular mechanism involved in cell cycle arrest at the G1 to the S phase transition in human monocytic leukaemia cells. A careful study of G1/ S transition regulatory proteins revealed an enhanced expression of the Cdk inhibitor p16/INK4a with a concomitant decrease of retinoblastoma protein phosphorylation, thus suggesting that both p16 and pRB proteins play an important role in G1 cell cycle arrest induced by this compound in human leukaemia cells. There were four studies of discodermolide, a compound originally isolated from the sponge Discodermia dissoluta that suppresses microtubule dynamics. Xia and colleagues 47 using a photoaffinity-labelled analogue to investigate and define the drug binding pocket in tubulin observed that whilst the analogue had no hypernucleation effect in an in vitro microtubule polymerisation assay, it labelled amino acid residues 305-359 in the S9-S10 loop in b-tubulin. This sequence is very close to the Taxol binding site, thus enabling the construction of a computationally derived binding model of both the discodermolide analogue and the native discodermolide binding to b-tubulin. Escuin and colleagues 48 observed that discodermolide, as well as other microtubule-disrupting agents, down-regulated hypoxia-inducible factor-1a (HIF-1a) protein levels, but not mRNA, in a dose-dependent manner. This study directly linked b-tubulin drug binding with HIF-1a protein inhibition, a discovery of considerable clinical significance because HIF-1a overexpression is present in over 70% of all human tumours and their metastasis, thus making HIF-1a 'a prime target for anticancer therapies'. Klein and colleagues 49 evaluated discodermolide in several human cancer cell lines and determined that it induced accelerated senescence with a potency similar to doxorubicin with concomitant Erk1/2 activation and up-regulation of two markers of senescence, namely the p66Shc and PAI-1 proteins. These findings provide the first demonstration of a microtubule stabilising agent that inhibits tumour cell growth by the mechanism of accelerated senescence. Huang and colleagues 50 investigated the combination of discodermolide and taxol in human ovarian cancer cells and an in vivo model of ovarian carcinoma, and reported that both agents interacted synergistically at drug concentrations that resulted in aneuploidy rather than mitotic arrest. Although the mechanism for the synergistic efficacy of these two agents was not determined, the data supported concurrent use of low doses of these two compounds for the treatment of epithelial ovarian carcinoma, a leading cause of death from gynaecologic malignancies. In an effort to develop novel therapies for poorly vascularised and hypoxic tumours, a 'longstanding problem in clinical oncology', Smith and colleagues 51 tested discodermolide analogues as potent chemical components of combination bacteriolytic therapy. Interestingly, a single i.v. injection of (+)-2,3 anhydrodiscodermolide plus genetically modified Clostridium novyi-NT spores into mice bearing colorectal cancer xenografts caused rapid and complete obliteration of the tumours. Nine studies were published during 2005-2006 on the preclinical and clinical evaluation of the dolastatins, a family of modified peptides originally isolated from the marine mollusk Dolabella auricularia that induce actin assembly in vivo. Watanabe and colleagues 52 investigated the antitumour activity of TZT-1027 (Soblidotin), a newly synthesised dolastatin 10 derivative, using a panel of human tumours that included Pgp overexpressing sublines. They concluded that TZT-1027 antitumour activity was superior to that of paclitaxel, docetaxel and vincristine, and thus anticipated that TZT-1027 would provide benefit in the chemotherapy of tubulin inhibitorunresponsive tumours. Five Phase I trials were conducted with TZT-1027 and a third-generation dolastatin-15 analogue, tasidotin hydrochloride (ILX651). Jonge and colleagues 53 in the Netherlands completed a Phase I and pharmacokinetic study with TZT-1027 in 17 patients with advanced solid tumours. In this trial, one patient with a refractory metastatic liposarcoma demonstrated a response, and eight patients experienced stabilisation of their tumour, and the study defined a dose of TZT-1027 that was 'well tolerated', with the main dose-limiting toxicities being reversible neutropaenia and infusion arm pain. A three-institution Phase I study with TZT-1027 in 18 Japanese patients with advanced solid tumours was reported by Tamura and colleagues. 54 The researchers noted that one patient with metastatic oesophageal cancer achieved a partial response, and that TZT-1027 was 'active at a tolerable dose' with neutropaenia and infusion reaction (phlebitis) the most frequent toxicities that were observed. Greystoke and colleagues 55 published data of a Phase I study with TZT-1027 administered in combination with carboplatin in 14 patients with advanced solid tumours, which resulted in one patient with pancreatic adenocarcinoma achieving a partial response. Although peripheral reversible neuropathy was observed in 36% of the patients, the combination of TZT-1027 and carboplatin appeared to be 'relatively well tolerated'. 71 found that the combination of ET-743 and irinotecan, a water-soluble derivative of camptothecin that targets topoisomerase I, resulted in only weak cytotoxicity to human rhabdomyosarcoma in vitro, but this same drug combination produced a 'strong and long-lasting' effect on the growth of rhabdomyosarcoma tumour xenografts in vivo. Although the mechanism of the in vivo synergism of ET-743 and irinotecan was not investigated, the authors hypothesised that the discrepancy between in vitro and in vivo effects might result from a combination of direct cytotoxic and indirect anti-inflammatory effects of ET-743. One Phase I and pharmacokinetic study as well as 6 Phase was generally well tolerated with reversible hepatotoxicity, the most common adverse effect (58% of patients). The observation that one patient with a recurrent Ewing sarcoma showed a complete response with resolution of pulmonary metastases has resulted in the development of a Phase II trial in children with refractory Ewing or soft tissue sarcomas. Garcia-Carbonero and colleagues 73 reported a Phase II and pharmacokinetic study with ET-743 in 36 previously untreated patients with advanced soft tissue sarcomas, mainly leiomyosarcoma and liposarcoma. ET-743 evidenced 'manageable' toxicity in this study, with one complete and five partial responses to ET-743 being observed (17.1% response rate). This led the investigators to state that ET-743 'demonstrates for the first time the safety, tolerability and antitumour activity' in chemotherapy-naïve patients with advanced soft tissue sarcomas when used as a single agent, and it justified 'some prudent optimism' for patients who fail doxorubicin or ifosfamide therapy. Huygh and colleagues 74 reported a retrospective Phase II study of 89 patients with advanced, pretreated soft tissue and bone sarcoma, who were treated with ET-743 as a 24-h continuous infusion. Whilst the toxicities were mainly an asymptomatic elevation of transaminases and neutropaenia, the treatment resulted in one complete remission, 5 partial remissions, one minimal response and 16 patients with disease stabilisation of 6 months or more, thus strongly suggesting that 'further evaluation of the activity of ET-743 in sarcomas is therefore warranted'. Le Cesne and colleagues 75 communicated a Phase II study with 104 patients from 8 European institutions with pretreated advanced soft tissue sarcomas that were provided with a 24-h continuous infusion every 3 weeks. The fact that 8 partial responses were observed in leiomyosarcomas, a tumour subtype usually considered to be resistant to doxorubicin and/or ifosfamide regimens, prompted the authors to 'demand(s) further evaluations' of ET-743 as a second-line agent and in combination studies. Sessa and colleagues 76 assessed the efficacy and toxicity of ET-743 in 59 patients with advanced ovarian cancer who had experienced treatment failure after platinum or taxane therapy. Using a Phase II 3-h infusion schedule every 3 weeks which allowed for outpatient administration, the study reported that ET-743 was tolerable with 'promising activity' in relapsed ovarian cancer, showing a 43% response rate in patients with platinum-insensitive disease. Zelek and colleagues 77 from 3 French institutions determined the activity of ET-743 in a Phase II study that investigated the use of this compound as a 24-h continuous i.v. infusion every 3 weeks in 27 patients with advanced breast cancer who were resistant or had relapsed after conventional chemotherapy. Although the partial response rate (14%) was judged to be modest, it was considered to be in the range of 'what can be expected for an active drug in this setting'. Tewari and colleagues 78 reported a remarkable case of activity of ET-743 when used as a single agent in one patient with refractory metastatic uterine leiomyosarcoma in whom 4 prior regimens had failed. The patient had a durable partial response lasting at least 8 months, and the authors concluded that ET-743's activity in uterine leiomyosarcomas definitely warrants further investigation.
One report in 2005-2006 examined the pharmacology of fascaplysin, an alkaloid obtained from the Papua New Guinea sponge Fascaplysinopsis reticulata. Subramanian and colleagues 79 showed therapeutic efficacy in a novel pharmacology paradigm designed to rapidly move prospective anticancer drugs from discovery phase through pharmacology testing and into therapeutic trial assessment, as well as complete proteomics analysis to reveal 'pathways involved in the drug's cytotoxicity'. Two reports extended the preclinical pharmacology of halichondrin B, a large polyether macrolide found in a variety of marine sponges. Jordan and colleagues 80 observed that ET389, a synthetic macrocyclic ketone analogue that is currently in Phases I and II clinical trials, inhibited microtubule polymerisation in an in vitro human breast cancer cell line. It significantly suppressed microtubule growth rate, length and duration, thus resulting in the suppression of the metaphase/anaphase transition. A putatively novel mechanism of action involving E7389's ability to 'aggregate tubulin and selectively suppress microtubule growing events' was proposed by the authors. Dabydeen and colleagues 81 examined the biochemical mechanism of action of E7389 in direct comparison with halichondrin B. They found that ET389 was more potent than halichondrin B in all biochemical assays, and by extensive molecular modelling studies gained new insight into the interaction of both compounds with a cleft between ab-heterodimers in tubulin. This interaction appeared to involve contacts with a-subunit residues Phe244, Ala247, Leu248, and Tyr257 and b-subunit residues Gli81, Pro82, Thr223 and Gly225. One report extended the pharmacology of the peptidic antimitotic agent hemiasterlin, a compound isolated from numerous marine sponges. Ravi and colleagues 82 reported progress in the structure-based identification of the tubulin binding site for HTI-286, a synthetic analogue of hemiasterlin.
They proposed a binding model of HTI-286 to key residues on b tubulin that appears to be supported by significant experimental data, including biophysical characterisation, photolabelling and NMR studies, and by biological activity data. One report extended the pharmacology of jasplakinolide (jaspamide), a cyclic depsipeptide originally isolated from Jaspis sponges, that induces actin polymerisation. Whilst investigating the anti-migratory potential of this agent, Hayot and colleagues 83 used an in vitro pharmacological strategy that included spectrofluorometry to monitor the kinetics of actin polymerisation, and videomicroscopy to investigate cell motility. that peloruside A bound to the laulimalide site on tubulin which is distinct from the taxoid site. Furthermore, the researchers found that although peloruside A and laulimalide were unable to synergise with each other, both compounds could act synergistically on tubulin assembly with taxoid site-binding marine agents such as discodermolide, dictyostatin and eleutherobin. This finding led the authors to conclude that other combinations of these agents may be worth investigating both preclinically and clinically.
In an effort to identify novel natural product-derived peroxisome proliferator-activated receptor c (PPRc) activators for breast cancer treatment, Mora and colleagues 89 investigated the effects of psammaplin A, a known histone deacetylase inhibitor originally isolated from the marine sponge Pseudoceratina rhax. Psammaplin A activated PPRc in a cellbased reporter assay and induced apoptosis in human breast cancer cells in vitro. This suggests that PPARc activators may provide new molecularly targeted lead compounds for the design of novel classes of antitumour agents. Table 1 also includes a number of marine natural products which were not previously reviewed:
2-4 aaptamine, polymeric alkylpyridinium salts, aplyronine A, bastadin 6, clavulone II, 13-deoxytedanolide, fucoxanthinol, geodiamolides, geoditin A, halocynthiaxanthin, ircinin-1, laxaphycins A and B, leptosins C and F, ningalins, onnamide A, philinopside A, salinosporamide A, stellettin A, strobilinin-felixinin and variolin B.
As a result of a screening effort to discover agents that target the cyclin-dependent kinase inhibitor Cip/Kip p21 protein, Aoki and colleagues 90 reported the isolation of a benzonaphthyridene alkaloid aaptamine from the Indonesian marine sponge Aaptos suberitoides. The in vitro studies demonstrated that aaptamine induced expression of p21 protein in a p53-independent manner, arresting the cell cycle at the G2/M phase. Paleari and colleagues 91 showed that polymeric alkylpyridinium salts isolated from the marine sponge Reniera sarai induced apotosis and cell-cell adhesion in non-small cell lung cancer cells. The selectivity of these polymeric alkylpyridinium salts, which were recently described as irreversible acetylcholinesterase inhibitors, towards cholinergic receptor-expressing tumours led the investigators to propose them as 'alternative inhibitors of lung cancer with low systemic toxicity'. Hirata and colleagues 92 extended the molecular characterisation of the sea hare metabolite aplyronine A, which had previously been shown to inhibit polymerisation of globular actin to fibrous actin. Using synchrotron X-ray analysis, the crystal structure of the actin-aplyronine A complex was investigated. Aplyronine A was observed to bind to a hydrophobic cleft by intercalating its aliphatic tail into the actin molecule, an interaction shown to be essential to depolymerise actin and for cytotoxicity against human HeLa tumour cell lines. Aoki and colleagues 93 described molecular pharmacology studies of bastadin 6, a macrocyclic and tetrameric bromotyrosine derivative isolated from the marine sponge Lanthella basta. 98 reported new mechanistic information on the cyclic peptides geodiamolides A, B, H and I isolated from the marine sponge Geodia corticostylifera from Brazil. The researchers noted that peptides A and H had potent antiproliferative activity against two human breast cancer cell lines (IC 50 = 18-90 nM) and disorganised F-actin filaments in a dose-dependent manner. Interestingly, normal cell lines did not show cytoskeleton alterations after treatment with the geodiamolides, thus suggesting a putative biomedical potential for these novel compounds.
As part of a research program to evaluate bioactive secondary metabolites of marine organisms, Liu and colleagues 99 compared the cytotoxicity of the isomalabaricane triterpenes geoditins A and B isolated from the marine sponge Geodia japonica. Geoditin A, which differs in an acetyl group at the C3 position with geoditin B, was found to be the most cytotoxic (IC 50 = 5 lg/ml) to human HL60 promyelocytic leukaemia cells, probably due to a dose-dependent increase of reactive oxygen species, a decrease in mitochondrial potential and caspase-3 mediated apoptosis.
In an effort to find new agents for the treatment of melanoma, Choi and colleagues 100 completed a detailed mechanistic study of ircinin-1, isolated from the marine sponge Sarcotragus sp. Ircinin-1 inhibited the growth of a human melanoma cell line in vitro, by a dual mechanism that involved the arrest of cell cycle progression at the G1 phase and induction of apoptosis via the Fas/Fas-L pathway. properties of synthetic analogues of the ningalins, aromatic alkaloids originally isolated from the marine ascidian Didemnum sp. By a mechanism that involved a direct and dosedependent interaction with the multidrug resistance drug transporter Pgp, the ningalins markedly enhanced the antitumour cytotoxicity of vinblastine, doxorubicin and taxol both in vitro and/or in vivo. This observation supported the proposition that these agents 'may allow the reduction in the dosage of anticancer drugs whilst enhancing or achieving a curative effect'. Whilst screening 20,000 samples for agents that might activate the tumour-suppressing transforming growth factor-b (TGF-b) signalling cascade, Lee and colleagues 104 discovered that onnamide A and theopederin B, isolated from the marine sponge Mycale sp., induced activation of the PAI-1 promoter gene, a well-characterised TGF-b-responsive gene. Since both onnamide A and theopederin B potently inhibited protein synthesis (IC 50 = 30 nM and 1.9 nM, respectively) and activated p38 kinase and c-Jun N-terminal kinase, as well as inhibited proliferation of several human cancer cell lines in the nanomolar range, the researchers concluded that these marine agents might serve as lead candidates for anticancer drug development. During a screening effort for potential angiogenesis inhibitors, Tong and colleagues 105 discovered a novel sulfated saponin philinopside A, isolated from the sea cucumber Pentacta quandrangulari, that possessed dual antiangiogenic and antitumour effects. Philinopside A inhibited angiogenesis (IC 50 = 0.98-1.4 lM) in human microvascular endothelial cells as well as tumour growth both in vitro (IC 50 = 1.5-2.4 lM) and in vivo by a synergistic mechanism that appeared to involve inhibition of 4 receptor tyrosine kinases (IC 50 = 2.6-4.9 lM). Macherla and colleagues 106 contributed structure-activity relationship (SAR) studies of salinosporamide A (NPI-0052), a novel marine bacterium-derived alkaloid shown to potently inhibit the proteasome, a multicatalytic proteolytic complex that is involved in the regulation of cellular protein degradation. With 16 analogues of salinosporamide A generated by either fermentation or derivatisation, SAR studies were completed using a variety of well-characterised cytotoxicity, proteasome inhibition and NF-jB activation assays. These studies demonstrated a marked reduction in potency resulting from the replacement of the chloroethyl group in salinosporamide A with nonhalogenated substituents. Liu and colleagues 107 reported novel preclinical pharmacology for the isomalabaricane triterpene stelletin A, isolated from the marine sponge Geodia japonica. These investigators observed differential cytotoxicity of stelletin A between human leukaemia HL-60 cells (IC 50 = 0.4 lg/ml) and human prostate cancer LNCaP cells (IC 50 = 120 lg/ml) with the concomitant up-regulation of the pro-apoptotic marker proteins, FasL and caspase-3. Interestingly, in HL-60 cells stelletin A stimulated a dose-dependent increase of the NADPH oxidase components and generation of reactive oxygen radicals. Jiang and colleagues 108 reported preclinical mechanism of action studies on the furanosesterterpene strobilinin-felixinin, which was isolated from the sponge Psammocinia sp. and was previously reported to display cytotoxicity towards several cancer cell lines. Cell cycle analysis revealed that the marine compounds arrested HeLa cells in the S phase, probably as a result of DNA synthesis inhibition, with topoisomerase I and polymerase a-primase, the 'two main target molecules'. Simone and colleagues 109 extended the molecular pharmacology of variolin B, a guanidine alkaloid isolated from the Antarctican marine sponge Kirkpatrickia variolosa. Both variolin B and its analogue deoxy-variolin B, which has greater stability and solubility, were shown to activate apoptosis in a p53-independent fashion. They appeared to preferentially inhibit cyclin-dependent kinases (CDK) 1/cyclin B, CDK2/cyclin A and CDK2/cyclin E. Thus, variolin B may be effective against tumours with mutation or deletion of the p53 gene. Oda and colleagues 110 extended the preclinical pharmacology of verrucarin A, isolated from a culture broth of the marine fungus Myrothecium roridum. Using human promyelocytic and erythroleukaemia cell lines, the investigators determined that verrucarin A's strong cytotoxicity against these cell lines was concomitant to inhibition of the p38 and C-Jun mitogenactivated protein kinases in the nanomolar range.
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2005-2006 Antitumour pharmacology of marine natural products with undetermined mechanisms of action 50 equal or less than 1.0 lg/ml), and whose structures are shown in Fig. 2 . The preclinical pharmacology completed with these marine compounds consisted mainly of in vitro and/or in vivo cytotoxicity testing with panels of either human or murine tumour cell lines. In a few reports, cytotoxicity studies were more extensive and included the National Cancer Institute 60-tumour cell line screen. It is clear that additional pharmacological testing will be required to help determine if the potent cytotoxicity observed with these marine chemicals resulted from a specific pharmacologic effect rather than a general toxic effect on the tumour cells used in these investigations. Although contrasting with the extensive preclinical and clinical investigations completed with the marine compounds presented in Table 1 , the mechanism of action research was reported for only a few of the compounds listed in 117, 118 and secalonic acid D inhibited the cell cycle at the G 0 /G 1 phase in a concentration-dependent manner. 120 Although less potent than the marine natural products as included in Table 2 , numerous additional reports were published during 2005-2006 describing novel structurally characterised molecules with cytotoxic activity (IC 50 ) mostly in the greater than 1-5.0 lg/ml range. Although only cytotoxicity against selected murine or human cancer cells was determined in vitro in the majority of these reports, mechanistic work was reported in a few of these studies, e.g. inhibition of Tie2 kinase, an enzyme that supports angiogenesis, by polybrominated diphenyl ethers; 121 
